Business Context and Reporting Period
Company: Ekso Bionics Holdings, Inc. (Note: Input metadata referenced "Chronoscale Corp," but the filing text identifies Ekso Bionics Holdings, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: October 28, 2025
Reporting Period: Event-based report regarding a registered direct offering.
Key Financial Metrics and Transaction Details
- Offering Size: 769,490 shares of Common Stock.
- Offering Price: $4.81 per share.
- Gross Proceeds: Approximately $3.7 million (calculated as 769,490 shares x $4.81).
- Net Proceeds: Approximately $3.2 million (after deducting fees and expenses).
- Placement Agent Fee: 6% of gross cash proceeds.
- Placement Agent Warrant: Warrant to purchase up to 15,389 shares at an exercise price of $4.81 per share.
- Use of Proceeds: General corporate purposes, including R&D, SG&A, strategic initiatives, and working capital.
Note: This filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics for the company's operations.
Material Changes
This filing reports a material capital event rather than operational changes. The primary change is the issuance of new equity securities and the creation of a warrant obligation to the placement agent. No prior comparable period data is provided in this document to assess operational changes.
Guidance, Outlook, and Risks
- Outlook: The company intends to utilize net proceeds for research and development and working capital needs.
- Closing Conditions: The offering is expected to close on or about October 30, 2025, subject to customary closing conditions.
- Risks/Contingencies: The Placement Agent Warrant Shares have not been registered under the Securities Act and may not be offered or sold in the U.S. absent registration or an applicable exemption. The filing notes that the Placement Agent and affiliates may provide future banking and advisory services for which fees will be received.
Investor Verification Checklist
- Verify the final closing date of the offering (expected October 30, 2025).
- Confirm the exact number of shares issued and final net proceeds after all expenses.
- Review the full text of the Placement Agent Warrant (Exhibit 4.1) for specific terms and exercise conditions.
- Check subsequent filings for any updates on the use of proceeds or changes in capital structure.